Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beclomethasone Dipropionate BAI in Persistent Asthma
NCT02513160Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate in asthma (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in 1 Second Area Under the Effect Curve From Time 0 to 6 Weeks. Started Sep 2015; status: completed.
02
Drugs
beclomethasone dipropionate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02513160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513160.